Sleep Disruption Pattern - Epilepsy Monitoring Unit
Launched by DUKE UNIVERSITY · Aug 29, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how sleep disruptions can affect seizures in people with epilepsy who have not been able to control their seizures with medication. Researchers want to find out if waking patients up with an alarm during sleep could lead to earlier seizures. This could help doctors understand more about seizure patterns and potentially decrease the amount of time patients need to stay in the hospital for monitoring.
To be part of this study, participants should be between 14 and 60 years old, be undergoing monitoring in a special epilepsy unit for surgery evaluations, and have seizures occurring 2 to 3 times a week. It's important that sleep is a known trigger for their seizures. Participants can expect to stay in a hospital where their sleep and seizure activity will be closely monitored as part of the research. The goal is to gather valuable information that could improve care for those with epilepsy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 14 to 60 years
- • EMU monitoring for presurgical evaluations
- • Average 2-3 seizures per week based on pre-admission seizure diary
- • Sleep as a known seizure trigger
- Exclusion Criteria:
- • - Multiple seizures a day based on pre-admission seizure diary
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Birgit Frauscher, MD PD
Principal Investigator
Duke University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported